On this resident blog, PGY2 SOT Elise Lawrence joins us from the University of Colorado Hospital to discuss a review of 3-year follow up data on outcomes after conversion from monthly to every 2-month belatacept maintenance therapy in low immunologic risk kidney transplant recipients, followed by a brief refresher on considerations for toxoplasmosis prophylaxis after solid organ transplant and what options to consider when patients can not utilize sulfamethoxazole-trimethoprim.